Tci Wealth Advisors, Inc. Sage Therapeutics, Inc. Transaction History

Tci Wealth Advisors, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$37.27 - $46.57 $2,497 - $3,120	67 Added 26.48%	320 $13,000
Q4 2022 Feb 06, 2023	BUY	$32.2 - $43.61 $1,642 - $2,224	51 Added 25.25%	253 $9,000
Q3 2022 Nov 08, 2022	BUY	$32.28 - $43.27 $32 - $43	1 Added 0.5%	202 $8,000
Q1 2022 Apr 29, 2022	BUY	$30.71 - $45.71 $6,172 - $9,187	201 New	201 $7,000
Q3 2021 Oct 29, 2021	SELL	$40.26 - $57.37 $2,053 - $2,925	-51 Closed	0 $0
Q2 2021 Aug 02, 2021	BUY	$54.88 - $79.29 $2,798 - $4,043	51 New	51 $3,000
Q2 2019 Jul 23, 2019	SELL	$157.85 - $183.09 $1,420 - $1,647	-9 Closed	0 $0
Q1 2019 Apr 11, 2019	BUY	$89.33 - $163.65 $803 - $1,472	9 New	9 $1,000
Q4 2018 Jan 17, 2019	SELL	$81.94 - $139.71 $491 - $838	-6 Closed	0 $0
Q3 2018 Nov 02, 2018	SELL	$138.11 - $169.04 $4,281 - $5,240	-31 Reduced 83.78%	6 $1,000
Q2 2018 Jul 27, 2018	BUY	$140.36 - $175.76 $5,193 - $6,503	37 New	37 $6,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.